458 related articles for article (PubMed ID: 34988021)
21. Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?
Tajaldini M; Saeedi M; Amiriani T; Amiriani AH; Sedighi S; Mohammad Zadeh F; Dehghan M; Jahanshahi M; Zanjan Ghandian M; Khalili P; Poorkhani AH; Alizadeh AM; Khori V
Eur J Pharmacol; 2022 Aug; 928():175087. PubMed ID: 35679891
[TBL] [Abstract][Full Text] [Related]
22. The Role of Tumor Associated Macrophages (TAMs) in Cancer Progression, Chemoresistance, Angiogenesis and Metastasis - Current Status.
Dallavalasa S; Beeraka NM; Basavaraju CG; Tulimilli SV; Sadhu SP; Rajesh K; Aliev G; Madhunapantula SV
Curr Med Chem; 2021; 28(39):8203-8236. PubMed ID: 34303328
[TBL] [Abstract][Full Text] [Related]
23. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
24. Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Qiu SQ; Waaijer SJH; Zwager MC; de Vries EGE; van der Vegt B; Schröder CP
Cancer Treat Rev; 2018 Nov; 70():178-189. PubMed ID: 30227299
[TBL] [Abstract][Full Text] [Related]
25. Tumor-Associated Macrophages: A Potential Target for Cancer Therapy.
Tan Y; Wang M; Zhang Y; Ge S; Zhong F; Xia G; Sun C
Front Oncol; 2021; 11():693517. PubMed ID: 34178692
[TBL] [Abstract][Full Text] [Related]
26. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing.
Zins K; Abraham D
Methods Mol Biol; 2020; 2115():289-325. PubMed ID: 32006408
[TBL] [Abstract][Full Text] [Related]
27. The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy.
Ge Z; Ding S
Front Oncol; 2020; 10():590941. PubMed ID: 33224886
[TBL] [Abstract][Full Text] [Related]
28. Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1R.
Nguyen HT; Gurvich N; Gillrie MR; Offeddu G; Humayun M; Kan EL; Wan Z; Coughlin MF; Zhang C; Vu V; Lee SWL; Tan SL; Barbie D; Hsu J; Kamm RD
bioRxiv; 2023 Nov; ():. PubMed ID: 38076998
[TBL] [Abstract][Full Text] [Related]
29. Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers.
Kielbassa K; Vegna S; Ramirez C; Akkari L
Front Immunol; 2019; 10():2215. PubMed ID: 31611871
[TBL] [Abstract][Full Text] [Related]
30. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
31. Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms.
Zheng J; Jiang J; Pu Y; Xu T; Sun J; Zhang Q; He L; Liang X
Front Bioeng Biotechnol; 2023; 11():1248421. PubMed ID: 37654704
[TBL] [Abstract][Full Text] [Related]
32. Targeting Tumor-Associated Macrophages in Cancer Immunotherapy.
Petty AJ; Owen DH; Yang Y; Huang X
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771482
[TBL] [Abstract][Full Text] [Related]
33. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy.
Xu L; Xie X; Luo Y
Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912
[TBL] [Abstract][Full Text] [Related]
34. [Melanoma-associated macrophages-from molecular signals to therapeutic application].
Chatziioannou E; Aydin SA; Forchhammer S; Sinnberg T; Eigentler T
Dermatologie (Heidelb); 2022 Dec; 73(12):915-928. PubMed ID: 36394590
[TBL] [Abstract][Full Text] [Related]
35. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy.
Wei X; Wang J; Liang M; Song M
Theranostics; 2022; 12(18):7821-7852. PubMed ID: 36451865
[TBL] [Abstract][Full Text] [Related]
36. Tumor-associated macrophages: implications in cancer immunotherapy.
Petty AJ; Yang Y
Immunotherapy; 2017 Mar; 9(3):289-302. PubMed ID: 28231720
[TBL] [Abstract][Full Text] [Related]
37. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
38. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy.
Gao J; Liang Y; Wang L
Front Immunol; 2022; 13():888713. PubMed ID: 35844605
[TBL] [Abstract][Full Text] [Related]
39. The effects of radiation therapy on the macrophage response in cancer.
Beach C; MacLean D; Majorova D; Arnold JN; Olcina MM
Front Oncol; 2022; 12():1020606. PubMed ID: 36249052
[TBL] [Abstract][Full Text] [Related]
40. The cross-talk between macrophages and tumor cells as a target for cancer treatment.
Aizaz M; Khan A; Khan F; Khan M; Musad Saleh EA; Nisar M; Baran N
Front Oncol; 2023; 13():1259034. PubMed ID: 38033495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
